Methods for antibody drug conjugation, purification, and formulation
Methods of producing, purifying, and formulating antibody drug conjugates (ADCs) are provided herein. The methods use continuous conjugation processes, single-pass tangential flow filtration, countercurrent diafiltration, and/or in-line process automation technologies. The methods decrease process times and costs and improve product consistency.
1. A continuous method for producing an antibody drug conjugate (ADC) composition comprising (i) conjugating an antibody or antigen-binding fragment thereof to a drug to form an ADC in a flow reactor, wherein one or more conjugation reagents are continuously added to the flow reactor, (ii) removing unconjugated drug, and (iii) exchanging the ADC into a stable buffer, wherein (i) to (iii) are performed continuously, and wherein single-pass tangential flow filtration (SPTFF), flow-through column-chromatography and/or countercurrent diafiltration is used to remove the unconjugated drug, wherein the ADC composition has an average drug-to-antibody ratio from 2 to 8; and wherein the ADC comprises an IgA, IgD, IgE, IgG, or IgM antibody or antigen-binding fragment thereof.
2. The method of claim 1 , wherein flow-through column chromatography is used to remove the unconjugated drug and SPTFF and/or countercurrent diafiltration is used to exchange the ADC into the stable buffer.
3. The method of claim 1 , further comprising pre-processing the antibody or antigen-binding fragment thereof or pre-processing the drug for conjugation, wherein the pre-processing is performed continuously with (i) to (iii) or is performed in bulk prior to (i) to (iii).
4. The method of claim 1 , further comprising pre-processing an antibody or antigen-binding fragment thereof wherein the pre-processing and (i) to (iii) are performed continuously.
5. The method claim 3 , wherein the pre-processing of the antibody or antigen-binding fragment thereof comprises exchanging the antibody or antigen-binding fragment thereof into a buffer for conjugation.
6. The method claim 3 , wherein the pre-processing of the antibody or antigen-binding fragment thereof comprises reducing the antibody or antigen-binding fragment thereof and/or oxidizing the antibody or antigen-binding fragment thereof.
7. A method for producing an antibody drug conjugate (ADC) composition in a continuous conjugation process, comprising (i) continuously adding one or more conjugation reaction reagents to an ADC conjugation reaction while the conjugation reaction proceeds and after at least one ADC has formed, wherein the conjugation reaction occurs in a flow reactor and (ii) continuously removing unconjugated drug using countercurrent diafiltration, wherein the ADC composition has an average drug-to-antibody ratio from 2 to 8; and wherein the ADC comprises an IgA, IgD, IgE, IgG, or IgM antibody or antigen-binding fragment thereof.
8. The method of claim 7 wherein the conjugation reaction reagent comprises an antibody or antigen-binding fragment thereof, a linker, or an antibody or antigen-binding fragment thereof attached to a linker.
9. The method of claim 7 , further comprising pre-processing an antibody or antigen-binding fragment thereof.
10. The method of claim 3 , wherein the pre-processing of the antibody or antigen-binding fragment thereof is performed continuously with (i) to (iii) and wherein the ADC is concentrated using single-pass tangential flow filtration and/or countercurrent diafiltration, the ADC is purified using single-pass tangential flow filtration and/or countercurrent diafiltration, and/or the ADC is transferred to a formulation buffer using single-pass tangential flow filtration and/or countercurrent diafiltration.
11. The method of claim 1 , wherein the method improves the consistency of the ADC production, decreases the time for ADC production, improves the consistency of the ADC production, decreases the time for ADC concentration, purification, or transfer and/or decreases the amount of buffer used.
12. The method of claim 1 , wherein the method further comprises in-line monitoring of an analyte.
13. The method of claim 1 , wherein the ADC is IMGN853 and the method comprises (i) mixing an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO:37 and a variable light chain comprising the amino acid sequence of SEQ ID NO:39 and N(2′)-deacetyl-N(2′)-(4-mercapto-4-methyl-1-oxopentyl) maytansine (DM4)-linked to N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB) in a continuous conjugation process to form IMGN853 (ii) concentrating IMGN853 using single-pass tangential flow filtration and/or countercurrent diafiltration, (iii) removing unconjugated drug from IMGN853 using single-pass tangential flow filtration and/or countercurrent diafiltration, and (iv) exchanging the IMGN853 into a formulation buffer using single-pass tangential flow filtration and/or countercurrent diafiltration.
14. The method of claim 1 , wherein the ADC is IMGN779 and the method comprises (i) mixing an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO:40 and a variable light chain comprising the amino acid sequence of SEQ ID NO:41 and DGN462-linked to sulfo-SPDB in a continuous conjugation process to form IMGN779, (ii) concentrating IMGN779 using single-pass tangential flow filtration and/or countercurrent diafiltration, (iii) removing unconjugated drug from IMGN779 using single-pass tangential flow filtration and/or countercurrent diafiltration, and (iv) exchanging the IMGN779 into a formulation buffer using single-pass tangential flow filtration and/or countercurrent diafiltration.
15. The method of claim 1 , wherein the ADC is IMGN632 and the method comprises (i) mixing an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO:42 and a variable light chain comprising the amino acid sequence of SEQ ID NO:43 and sulfonated DGN549C in a continuous conjugation process to form IMGN632, (ii) concentrating IMGN632 using single-pass tangential flow filtration and/or countercurrent diafiltration, (iii) removing unconjugated drug from IMGN632 using single-pass tangential flow filtration and/or countercurrent diafiltration, and (iv) exchanging the IMGN632 into a formulation buffer using single-pass tangential flow filtration and/or countercurrent diafiltration.
16. The method of claim 1 , wherein the method comprises increasing a first temperature of a conjugation process by at least 5° C. to an elevated temperature, wherein the elevated temperature is maintained for no more than 20 minutes.
17. The method of claim 1 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to FOLR1.
18. The method of claim 1 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to CD33.
19. The method of claim 1 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to CD123.
20. The method of claim 1 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to FOLR1, CD33, CD123, CD37, CD19, cMET, ADAM9, or HER2.
21. The method of claim 7 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to FOLR1.
22. The method of claim 7 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to CD33.
23. The method of claim 7 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to CD123.
24. The method of claim 7 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to FOLR1, CD33, CD123, CD37, CD19, cMET, ADAM9, or HER2.
25. The method of claim 1 , wherein the drug is a maytansinoid, a maytansinoid analog, a benzodiazepine, a pyrrolobenzodiazepine, a taxoid, CC-1065, a CC-1065 analog, a duocarmycin, a duocarmycin analog, a enediyne, a dolastatin, a dolastatin analog, a tomaymycin derivative, a leptomycin derivative, methotrexate, cisplatin, carboplatin, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil, or a morpholino doxorubicin.
26. The method of claim 1 , wherein the ADC comprises a linker that is a disulfide linker, a thioether linker, an acid labile linker, a photolabile linker, a peptidase labile linker, or a esterase labile linker.
27. The method of claim 25 , wherein the ADC comprises a linker that is a disulfide linker, a thioether linker, an acid labile linker, a photolabile linker, a peptidase labile linker, or a esterase labile linker.
28. The method of claim 25 , wherein the ADC binds to FOLR1, CD33, CD123,_CD37, CD19, cMET, ADAM9, or HER2.
29. The method of claim 27 , wherein the ADC binds to FOLR1, CD33, CD123, CD37, CD19, cMET, ADAM9, or HER2.
30. The method of claim 6 , wherein the reducing and/or the oxidizing are achieved without using SPTFF or countercurrent diafiltration.
31. The method of claim 6 , wherein the reducing and/or the oxidizing are achieved using only one SPTFF or countercurrent diafiltration step.
32. The method of claim 13 , wherein in-line monitoring is used to measure the concentration of the antibody added to the conjugation reaction, to measure the concentration of unconjugated drug in the retentate, to measure the concentration of unconjugated drug in the retentate, and/or to measure the concentration of impurities in the retentate.
33. The method of claim 7 , wherein the drug is a maytansinoid, a maytansinoid analog, a benzodiazepine, a pyrrolobenzodiazepine, a taxoid, CC-1065, a CC-1065 analog, a duocarmycin, a duocarmycin analog, a enediyne, a dolastatin, a dolastatin analog, a tomaymycin derivative, a leptomycin derivative, methotrexate, cisplatin, carboplatin, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil, or a morpholino doxorubicin.
34. The method of claim 7 , wherein the ADC comprises a linker that is a disulfide linker, a thioether linker, an acid labile linker, a photolabile linker, a peptidase labile linker, or a esterase labile linker.
35. The method of claim 33 , wherein the ADC comprises a linker that is a disulfide linker, a thioether linker, an acid labile linker, a photolabile linker, a peptidase labile linker, or a esterase labile linker.
36. The method of claim 33 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to FOLR1, CD33, CD123, CD37, CD19, cMET, ADAM9, or HER2.
37. The method of claim 35 , wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to FOLR1, CD33, CD123, CD37, CD19, cMET, ADAM9, or HER2.
38. The method of claim 7 , wherein the conjugation reaction reagent is a drug attached to a linker or a drug.
39. A method for producing an antibody drug conjugate (ADC) composition in a continuous conjugation process, comprising (i) continuously adding one or more conjugation reaction reagents to an ADC conjugation reaction while the conjugation reaction proceeds and after at least one ADC has formed, wherein the conjugation reaction occurs in a flow reactor and (ii) continuously removing unconjugated drug using single-pass tangential flow filtration (SPTFF), wherein the ADC composition has an average drug-to-antibody ratio from 2 to 8; and wherein the ADC comprises an IgA, IgD, IgE, IgG, or IgM antibody or antigen-binding fragment thereof.